---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-095275"
form_type: "8-K"
ticker: "MNOV"
cik: "0001226616"
company_name: "MEDICINOVA INC"
filed_at: "2022-04-05T23:59:59+00:00"
generated_at: "2026-06-26T09:20:41.058645+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MediciNova may receive portion of Genzyme's damages from Novartis Zolgensma patent suit

## Summary
- Genzyme filed First Amended Complaint on Feb 23, 2022 in Delaware court adding U.S. Patent No. 9,051,542 against Novartis over Zolgensma.
- MediciNova, as successor to Avigen, assigned patents to Genzyme in 2005 and may receive a portion of any damages recovered.
- Lawsuit targets unauthorized use of rAAV vectors for gene therapy drug Zolgensma.
- No guarantee of payment; contingent on Genzyme's recovery via settlement or judgment.

## SEC filing metadata
- accession: 0001193125-22-095275
- form_type: 8-K
- ticker: MNOV
- cik: 0001226616
- company_name: MEDICINOVA INC
- filed_at: 2022-04-05T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1226616/000119312522095275/0001193125-22-095275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1226616/000119312522095275/d681432d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-095275
- JSON: https://secwatch.observer/filing/0001193125-22-095275.json
- Plain text: https://secwatch.observer/filing/0001193125-22-095275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.